Symbiotec Pharmalab Limited (SYMBIOTEC)

Loading page…

Symbiotec Pharmalab Limited (SYMBIOTEC) · mywealthgrid

About

Symbiotec Pharmalab Limited operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹2

Market cap

₹7,703 Cr

P/E

70.8×

P/B

6.5×

Dividend yield

ROE

11.1%

ROCE

15.9%

Debt / equity

0.34

OPM

27.4%

EPS (TTM)

₹17.3

Book value

₹183.2

52-week high

—

52-week low

—

19 historical price candles were omitted because the exchange source has not been verified.

₹1,198.0+4.7%1Y

Quick read

rule-based

Pros

+Healthy operating margin of 27.4%

Cons

−Expensive at 70.8× trailing earnings

Research score

Structured signal from quality, growth, valuation and momentum.

34/100

Business quality: 53
Valuation: 14

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated figures · ₹ crore

₹ Cr	Mar 2024	Mar 2025	Mar 2026
	716	752	869
	545	550	631
Operating profit (EBITDA)	171	202	238
OPM %	23.9%	26.9%	27.4%
Depreciation	39	43	53
Interest	7	16	25
	7	4	3
Profit before tax	—	—	—
Tax	31	50	45
	100	-0	100
PAT margin %	14%	-0%	11.5%
EPS (₹)	18	17.4	19.1

₹ Cr	Mar 2024	Mar 2025	Mar 2026
Equity capital	11	11	13
Reserves	704	804	1,137
	247	541	388
	333	224	243
Total equity & liabilities	1,295	1,580	1,781
	411	402	1,084
CWIP	208	568	64
Investments	0	1	4
	675	608	627
Total assets	1,295	1,580	1,781

Compounded sales growth

7 years: —
5 years: —
3 years: —
1 year: 16%

Return on equity

7 years: —
5 years: —
3 years: 8%
Last year: 9%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated figures

Ratio	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—
EBITDA margin %	23.9%	26.9%	27.4%
EBIT margin %	18.5%	21.1%	21.2%
PAT margin %	14%	-0%	11.5%
Working capital
Receivable days	64	85	83
Inventory days	225	174	137
Payable days	—	—	—
NWC days	—	—	—
Leverage
Current ratio	1.45	1.04	0.92
Debt to EBITDA	1.44	2.68	1.63
Debt to equity	0.35	0.66	0.34
Interest coverage	19.3	10.2	7.4
Asset turnover	0.55	0.48	0.49
Return ratios
Return on assets %	7.7%	-0%	5.6%
Return on capital employed %	14.8%	15.9%	15.9%
Return on equity %	14%	-0%	8.7%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Jun 2026
	33.28%
	21.08%
	27.52%
Government	0%
	18.12%
No. of shareholders	4,27,730

Promoter holding up 0 percentage points since Jun 2026.

4 deals · 1 Sept 2026 – 2 Sept 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
2 Sept 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Sell	3,57,516	₹1,123.68	₹40.17 Cr
2 Sept 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Buy	3,57,516	₹1,123.40	₹40.16 Cr
1 Sept 2026	IRAGE BROKING SERVICES LLP	Bulk	BSE	Buy	5,94,402	₹1,054.55	₹62.68 Cr
1 Sept 2026	IRAGE BROKING SERVICES LLP	Bulk	BSE	Sell	4,17,890	₹1,096.07	₹45.80 Cr

1–4 of 4

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Anil SatwaniDirector
Mr. Rohit MantriDirector
Mr. Dhananjay MungaleDirector
Ms. Sunita KishnaniDirector
Mr. Pratik PatelDirector
Ms. Pramod KasatDirector
Salil JainCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Schemes holding

across 7 fund houses

Held by these funds

2.93%

of the company's equity

All mutual funds

5.54%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

no prior month

31 schemes · 7 fund houses

		Shares
Small Cap Fund	ICICI Prudential Mutual Fund	6.07 L	60	0.61%	0.944%	—
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	4.87 L	48.09	0.59%	0.757%	—
FLEXI CAP FUND	Tata Mutual Fund	1.58 L	15.62	0.43%	0.246%	—
Focused Fund	Baroda BNP Paribas Mutual Fund	1.02 L	10.11	1.53%	0.159%	—
INDIA PHARMA & HEALTHCARE FUND	Tata Mutual Fund	1.01 L	10	0.64%	0.157%	—
IB29-Groww Multicap Fund	Groww Mutual Fund	70,860	7	0.47%	0.11%	—
Health and Wellness Fund	Baroda BNP Paribas Mutual Fund	60,720	6	1.18%	0.094%	—
(LIVE SCHEMES)	ITI Mutual Fund	50,610	5	0.31%	0.079%	—

1–8 of 31

1 / 4

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Investor Presentation and earnings call

Sept 2026Transcript AI Summary PPT REC

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results21 Sept 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

20 announcementsExport CSV

21 Sept 2026, 7:07 pmResult

Results - Financials For Quarter Ended Jun 30, 2026

Financial Results PDF

21 Sept 2026, 6:32 pmBoard Meeting

Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On Monday, September 21, 2026

Outcome of Board Meeting PDF

17 Sept 2026, 6:56 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

12 Sept 2026, 10:27 amInsider Trading / SAST

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 PDF

11 Sept 2026, 4:17 pmBoard Meeting

Board Meeting Intimation for Prior Intimation Of The Meeting Of The Board Of Directors Of Symbiotec Pharmalab Limited ('The Company') To Be Held On September 21, 2026

Exchange filing PDF

11 Sept 2026, 12:30 pmInsider Trading / SAST

Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 PDF

3 Sept 2026, 1:47 pmCompany Update

Update On Intimation Under Regulation 8(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015.

General PDF

2 Sept 2026, 5:05 pmInsider Trading / SAST

Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 PDF

Date	Category	Subject	Filing
21 Sept 2026, 7:07 pm	Result Financial Results	Results - Financials For Quarter Ended Jun 30, 2026	PDF
21 Sept 2026, 6:32 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On Monday, September 21, 2026

Loading announcements…

Ratio	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—
EBITDA margin %	23.9%	26.9%	27.4%
EBIT margin %	18.5%	21.1%	21.2%
PAT margin %	14%	-0%	11.5%
Working capital
Receivable days	64	85	83
Inventory days	225	174	137
Payable days	—	—	—
NWC days	—	—	—
Leverage
Current ratio	1.45	1.04	0.92
Debt to EBITDA	1.44	2.68	1.63
Debt to equity	0.35	0.66	0.34
Interest coverage	19.3	10.2	7.4
Asset turnover	0.55	0.48	0.49
Return ratios
Return on assets %	7.7%	-0%	5.6%
Return on capital employed %	14.8%	15.9%	15.9%
Return on equity %	14%	-0%	8.7%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Symbiotec Pharmalab Limited

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Compounded returns

Compounded sales growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Investor Presentation and earnings call

Events

Board meetings1

Announcements

Announcements

Investor Presentation and earnings call

Board meetings1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

Profit & loss

Balance sheet

Compounded returns

Compounded sales growth

Return on equity

1

1